CONTROL NETs is two non-comparative parallel group phase II randomised open label trials of PRRT and CAPTEM in two cohorts of NET patients. Cohort A is comprised of patients with low to intermediate grade pancreatic neuroendocrine tumours (pNETs) randomised to receive PRRT + CAPTEM or CAPTEM alone. Cohort B is comprised of patients with low to intermediate grade midgut neuroendocrine tumours (mNETs) randomised to receive PRRT + CAPTEM or PRRT alone.

See ANZCTR for full trial details >

 

Trial Summary:

To determine the relative activity of capecitabine and temozolomide (CAPTEM)/ 177Lu-Octreotate peptide receptor radionuclide therapy (PRRT) in biopsy-proven, low to intermediate grade, unresectable, metastatic 68Ga-octreotate PET-avid pancreatic and midgut Neuroendocrine Tumours (NETs).

To inform future comparative phase III randomised controlled trials (RCTs) to determine the optimal therapies in pancreatic and midgut NETs.

Supported By:

Unicorn Foundation; AGITG; NHMRC CTC

Eligibility:

Consenting adult patients with advanced, unresectable low or intermediate grade (Ki-67)

Registration ID:

NCT02358356

Participation:

ANZ

Australian Lead Group:

AGITG

Status:

In follow-up

Activation Date:

 

Chairs:

Nick Pavlakis and J Harvey Turner

Contact:

controlnets.study@sydney.edu.au